Home - EVŌQ

We kill the world's worst superbugs

without creating antimicrobial resistance.

Recent news.

View More News

Engineering novel nanoparticles for the life, materials, and textile science industries.

"Antimicrobial resistance, I do believe, is the existential threat of this century.”

Admiral Brett P. Giroir
Former Assistant U.S. Secretary of Health

Multi-patented, high-volume laser nanofabrication process.

EVŌQ Nano is a nanoscience company that creates uniform, stable, sub-10 nm nanoparticles for a wide range of applications.

Our patented nanofabrication process requires only laser energy, ultrapure water, and pure silver metal. Ablation via a multiple, cross-laser system occurs at temperatures and pressures akin to diamond formation. The single-step, high-volume laser process generates stable, pure metal nanoparticles directly into pharmaceutical-grade water.

The Niedermeyer Discovery

Leadership

Shaun Rothwell, Chairman & CEO
Jeff Bennion, Chief Financial Officer
David Nilson, Chief Development Officer
William Niedermeyer, Founder & Chief Technology Officer
Kami Ball, Financial Controller
Steve Savage, President of FUZE Technologies
Andrew Peterson, Chief Technical Officer
Charles Wright, President of Medtech & Bio
Nate Kerr, Vice President of Medical Operations

Meet Our Team

Investors, Partners, and Affiliations

EVŌQ Nano is backed by $20 million in seed funding. The company has several R&D partnerships.

Our technology.

EVQ-218: The world's first and only non-ionic silver nanoparticle.

EVŌQ Nano has developed EVQ-218, unlocking the full therapeutic potential of silver without its detrimental tradeoffs.

While silver’s antibacterial qualities have been known for centuries, it is widely established that the antimicrobial activity is due to ion emission, which poses toxicity risks for biomedical and consumer product applications.^1-4

Compared to traditional nanosilvers, EVQ-218 is differentiated by dissolution and surface chemistry as the first stable, nonemissive, pure silver nanoparticle, making it a superior candidate for biomedical and consumer product use.⁵

Novel Mechanism of Action

Antimicrobial efficacy against the world's worst superbugs.

Combating Pulmonary Bacterial Infections.

The first therapeutic in development using EVQ-218 is for the treatment of pulmonary bacterial infections in patients with cystic fibrosis. Supported by 2 grants from the Cystic Fibrosis Foundation, research found an inhaled therapeutic using EVQ-218 demonstrated efficacy against pathogens linked to pulmonary infections:

Killed 64 strains from 9 known drug-resistant bacteria, including: – Pseudomonas, Burkholderia, MSSA, MRSA, NTM, Achromobacter, Stenotrophomonas, Candida, and Scedosporium.
Showed efficacy against 14 biofilms tested.
Eradicated multiple yeast and filamentous fungi.
Exhibited no toxicity in lung epithelial cells.
Developed no bacterial resistance during 28-day testing assay. Resistance to other antibiotics typically occurs in 4-5 days.^6-10

NANOTHERAPEUTICS PIPELINE

EVŌQ Bio’s novel platform has the potential to enable therapeutic development for a broad spectrum of diseases.

DISEASE INDICATION

TARGET

R&D

IND ENABLING

Pulmonary Infection
(Cystic Fibrosis)

Pseudomonas aeruginosa Burkholderia cepacia Stenotrophomonas

Pulmonary Infection
(Bacterial Pneumonia)

Streptococcus pneumoiae
Streptococcus aureus
Streptococcus pyogenes
Klebsiella pneumoniae
Haemophilus influenzae

Pulmonary Infection
(Fungal)

Candida albicans
Aspergillus

Tuberculosis

Mycobacterium
tuberculosis

Cellulitis

Group A ß-hemolytic
streptococcus
Streptococcus pneumoiae

Staph MRSA
(Skin)

Methicillin-resistant
Staphylococcus aureus

Diabetic Foot Ulcer

Staphylococcus aureus
Streptococcus aureus
Pseudomonas aeruginosa

Seasonal Flu

Influenza A

COVID-19

SARS-CoV2

Equipping medical devices with antimicrobial properties.

Targeting Healthcare-Associated Infections (HAIs).

EVOQ Nano’s antimicrobial nanoplatform is well positioned to target the 1 million healthcare-associated infections (HAIs) caused by indwelling urinary catheters annually in the U.S.¹¹ Bloodstream, pulmonary, and urinary tract infections are a significant cause of morbidity and increased mortality globally.¹²

The Impact.

For infections that are multidrug resistant, the Centers for Disease Control and Prevention (CDC) estimates treatment costs exceed $55 billion annually.¹³
Up to 1/3 of all catheter-associated urinary tract infections (CAUTI) in the U.S. are drug resistant,¹¹ with annual treatment cost exceeding $13 billion.¹³
Treatment costs for central line-associated bloodstream infections (CLABSI) from central-venous subclavian, internal jugular, and femoral catheters¹⁴ are estimated to exceed $12 billion annually.¹³

Current antibacterial catheters externally coated with silver lose efficacy once inserted, due to natural sloughing of the material coupled with the short life of silver ion emissions. This combination hinders the antimicrobial activity of current products. By embedding EVŌQ MedTech’s nanoparticles directly into the polymer used to make tubing and catheters, manufacturers can combat drug-resistant bacteria and significantly reduce HAI incidence.

Media Contact
Capwell Communications
[email protected]

EPA-approved antimicrobial treatment that's safe and sustainable.

Antimicrobial solutions for textiles and surfaces.

FUZE Technologies is an antimicrobial solutions company serving the textile, hospitality, fitness, and workspace industries. Its EPA-approved antimicrobial technology is free of chemicals, toxicity, and environmental waste. The company has secured contracts with some of the world’s most notable brands, including Nike, Adidas, the New England Patriots, Marriott, and Hilton.

FUZE Website